Maastricht Radiation Oncology
108
11
19
63
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
22.2%
24 terminated/withdrawn out of 108 trials
72.4%
-14.1% vs industry average
4%
4 trials in Phase 3/4
2%
1 of 63 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (108)
Lab Research Using Mini-tumors to Study Prostate Cancer Treatments
Role: lead
Registry Maastro Applicator
Role: lead
Effect of stRess and exeRcize on the Outcome After Chemo-Radiation
Role: lead
Vestibular Schwannoma Organoids
Role: lead
A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors
Role: lead
Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and Adjuvant Durvalumab: A Prospective Observational Phase II Trial
Role: lead
The Head and Neck Tumor Biobank
Role: lead
The Effect of 360° Virtual Reality Movies on Fear and Anxiety
Role: lead
PREselection of Patients at Risk for COgnitive DEcline After Radiotherapy Using Advanced MRI
Role: lead
Personal Health Train for Radiation Oncology in India and The Netherlands
Role: lead
Predicting Radiological Extranodal Extension in Oropharyngeal Carcinoma Patients Using AI
Role: lead
Feasibility of the Maastro Applicator in Rectal Cancer
Role: lead
Precision Radiation Treatment for Epilepsy (PRECISION)
Role: lead
Outcome Prediction in Head&Neck Cancer Patients After Radiotherapy
Role: lead
DETECT: Target Volume for Rectal Endoluminal Radiation Boosting
Role: lead
Lung Cancer Organoids and Patient Derived Tumor Xenografts
Role: lead
Elderly With Locally Advanced Lung Cancer: Deciding Through Geriatric Assessment on the Optimal Treatment Strategy
Role: lead
Biobank Carcinoma: Storing Blood and Protein of Patients With Cancer
Role: lead
In Vivo Treatment Verification of Brachytherapy
Role: lead
Developing Breast (Cancer) Organoids
Role: lead